[
  {
    "ts": null,
    "headline": "Fidelity Balanced Fund Q2 2025 Commentary",
    "summary": "Fidelity Investments reports a 2.74% Q1 loss for its Balanced Fund. See how equity picks and bond strategy shaped results. Review the full update.",
    "url": "https://finnhub.io/api/news?id=a8c74b2643fa75761f001aefff25b82d418a05756262be856f32dae651db4c17",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753476000,
      "headline": "Fidelity Balanced Fund Q2 2025 Commentary",
      "id": 136092560,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1383095217/image_1383095217.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "Fidelity Investments reports a 2.74% Q1 loss for its Balanced Fund. See how equity picks and bond strategy shaped results. Review the full update.",
      "url": "https://finnhub.io/api/news?id=a8c74b2643fa75761f001aefff25b82d418a05756262be856f32dae651db4c17"
    }
  },
  {
    "ts": null,
    "headline": "Integer Holdings Q2 Earnings Miss Estimates, Revenues Up Y/Y",
    "summary": "ITGR posts strong second-quarter revenue growth, but EPS misses estimate despite solid segment momentum.",
    "url": "https://finnhub.io/api/news?id=dfa076a62a9c44544c1207a916be7df2c1830818bcbf2baa3ed3b3cfbe604f3a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753460580,
      "headline": "Integer Holdings Q2 Earnings Miss Estimates, Revenues Up Y/Y",
      "id": 136090898,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "ITGR posts strong second-quarter revenue growth, but EPS misses estimate despite solid segment momentum.",
      "url": "https://finnhub.io/api/news?id=dfa076a62a9c44544c1207a916be7df2c1830818bcbf2baa3ed3b3cfbe604f3a"
    }
  },
  {
    "ts": null,
    "headline": "How Boston Scientific's Loss Was Edwards Lifesciences' Gain In the Second Quarter",
    "summary": "How Boston Scientific's Loss Was Edwards Lifesciences' Gain In the Second Quarter",
    "url": "https://finnhub.io/api/news?id=8e1cf44334d1b6f2017e2f0ab7aca0ff2502403bb5895caa3cc4bc76c5aad892",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753460016,
      "headline": "How Boston Scientific's Loss Was Edwards Lifesciences' Gain In the Second Quarter",
      "id": 136122989,
      "image": "",
      "related": "BSX",
      "source": "DowJones",
      "summary": "How Boston Scientific's Loss Was Edwards Lifesciences' Gain In the Second Quarter",
      "url": "https://finnhub.io/api/news?id=8e1cf44334d1b6f2017e2f0ab7aca0ff2502403bb5895caa3cc4bc76c5aad892"
    }
  },
  {
    "ts": null,
    "headline": "Venous Thromboembolism Treatment Devices Market Insights, Competitive Landscape, and Forecast Report 2032 Featuring Abbott, Boston Scientific, AngioDynamics, Argon Medical Devices, and Medtronic",
    "summary": "The Venous Thromboembolism Treatment Devices Market is poised for significant growth, projected to expand at a CAGR of 8.31% from 2025 to 2032. Factors such as rising deep vein thrombosis and pulmonary embolism rates, fueled by aging populations, sedentary lifestyles, and chronic diseases, drive demand. Key market players are innovating with advanced devices, enhancing treatment effectiveness. North America leads the market owing to technological advancements and high disease prevalence. Notable",
    "url": "https://finnhub.io/api/news?id=129609ac9ded3ebd6a9c645a90ed70bbf28b0f1a3158486a2cdbc8e7bad1ca16",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753456380,
      "headline": "Venous Thromboembolism Treatment Devices Market Insights, Competitive Landscape, and Forecast Report 2032 Featuring Abbott, Boston Scientific, AngioDynamics, Argon Medical Devices, and Medtronic",
      "id": 136088609,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The Venous Thromboembolism Treatment Devices Market is poised for significant growth, projected to expand at a CAGR of 8.31% from 2025 to 2032. Factors such as rising deep vein thrombosis and pulmonary embolism rates, fueled by aging populations, sedentary lifestyles, and chronic diseases, drive demand. Key market players are innovating with advanced devices, enhancing treatment effectiveness. North America leads the market owing to technological advancements and high disease prevalence. Notable",
      "url": "https://finnhub.io/api/news?id=129609ac9ded3ebd6a9c645a90ed70bbf28b0f1a3158486a2cdbc8e7bad1ca16"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Keeps Hitting Highs Amid Tesla, Google, Trade Deals: Weekly Review",
    "summary": "The S&P 500 and Nasdaq hit fresh highs last week, aided by Trump trade deals. Google, ServiceNow and GE Vernova were earnings winners. Tesla tumbled.",
    "url": "https://finnhub.io/api/news?id=8170a15d0ff8c3d88c968aef6c4d19de69adc01d7901d9101f0d09da7952f5e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753454728,
      "headline": "Stock Market Keeps Hitting Highs Amid Tesla, Google, Trade Deals: Weekly Review",
      "id": 136088492,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The S&P 500 and Nasdaq hit fresh highs last week, aided by Trump trade deals. Google, ServiceNow and GE Vernova were earnings winners. Tesla tumbled.",
      "url": "https://finnhub.io/api/news?id=8170a15d0ff8c3d88c968aef6c4d19de69adc01d7901d9101f0d09da7952f5e4"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific's (NYSE:BSX) investors will be pleased with their solid 173% return over the last five years",
    "summary": "The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...",
    "url": "https://finnhub.io/api/news?id=e0018b13336f1df25e2cc539620b1d665a6c736d1bfdb33d4992e48de72d7566",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753441225,
      "headline": "Boston Scientific's (NYSE:BSX) investors will be pleased with their solid 173% return over the last five years",
      "id": 136085062,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...",
      "url": "https://finnhub.io/api/news?id=e0018b13336f1df25e2cc539620b1d665a6c736d1bfdb33d4992e48de72d7566"
    }
  },
  {
    "ts": null,
    "headline": "U.S. Acute External Ventricular Drain Market Analysis Report 2025-2030 Featuring Medtronic, Integra, LifeSciences, Anuncia Medical, Natus, Fuji Systems, B Braun/Aesculap, Boston Scientific, Abbott",
    "summary": "The U.S. acute external ventricular drain market, valued at USD 86.5 million in 2024, is set to grow at a CAGR of 7.9% from 2025 to 2030. Growth is driven by increased demand for noninvasive neurosurgeries, technological innovations, and rising healthcare spending. Favorable reimbursement policies and an aging population further fuel market expansion. U.S. Acute External Ventricular Drain Market U.S. Acute External Ventricular Drain Market Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The \"U.S. Acut",
    "url": "https://finnhub.io/api/news?id=7c4701b878990b06be67ef096b1ab67b505046912b391faa02130abaee324222",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753435620,
      "headline": "U.S. Acute External Ventricular Drain Market Analysis Report 2025-2030 Featuring Medtronic, Integra, LifeSciences, Anuncia Medical, Natus, Fuji Systems, B Braun/Aesculap, Boston Scientific, Abbott",
      "id": 136084939,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The U.S. acute external ventricular drain market, valued at USD 86.5 million in 2024, is set to grow at a CAGR of 7.9% from 2025 to 2030. Growth is driven by increased demand for noninvasive neurosurgeries, technological innovations, and rising healthcare spending. Favorable reimbursement policies and an aging population further fuel market expansion. U.S. Acute External Ventricular Drain Market U.S. Acute External Ventricular Drain Market Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The \"U.S. Acut",
      "url": "https://finnhub.io/api/news?id=7c4701b878990b06be67ef096b1ab67b505046912b391faa02130abaee324222"
    }
  }
]